Anti-vascular endothelial growth factor drugs for retinal conditions a therapeutic review
Now, with the availability of observational studies and randomized clinical trials evaluating intravitreal bevacizumab, and the recent approval of an additional anti-VEGF (vascular endothelial growth factor) for retinal conditions (aflibercept), there is interest in assessing the clinical and cost-e...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
July 2015, 2015
|
| Series: | CADTH therapeutic review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Now, with the availability of observational studies and randomized clinical trials evaluating intravitreal bevacizumab, and the recent approval of an additional anti-VEGF (vascular endothelial growth factor) for retinal conditions (aflibercept), there is interest in assessing the clinical and cost-effectiveness of anti-VEGF drugs for the treatment of retinal conditions. This project will include a review of the clinical effectiveness of anti-VEGF drugs for the treatment of retinal conditions as well as an economic evaluation. This evidence will be used by the Canadian Drug Expert Committee (CDEC) to develop recommendations regarding the reimbursement of anti-VEGF drugs by public payers in Canada |
|---|---|
| Physical Description: | 1 PDF file (9 pages) |